Gilead Sciences (GILD): Cutting Numbers Slightly on Slower Switching - Leerink

Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but cut the price target to $112.00 from $114.00. The analyst underestimated the company’s US volume growth but also overestimated the rate of switching from legacy products onto new TAF-based regimens. As a result of the updates, the analyst now forecasts a slightly lower Revenue/TRx trend due to slower-than-expected switching to TAF based regimens from legacy combinations.

The analyst is expecting Gilead’s HIV products to generate WW sales of $20.5bn in 2021E vs. the previous forecast of $22.6bn.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $81.47 yesterday.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
• Ladenburg Thalmann Starts Spire (SR) at Neutral